CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
High ImpactOriginal article

Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M

RegulatoryCRLrelabotulinumtoxinANegative
AI Analysis

Summary

Galderma received a complete response letter from the FDA for its anti-wrinkle drug relabotulinumtoxinA. Separately, Kimball acquired a CDMO for $103 million.

Outcome Details

Complete response letter from FDA for relabotulinumtoxinA

Importance:8/10
Sentiment:
-0.70
FDA decisionCRLneuromodulatorM&ACDMO
Related Companies

Read the original article

Published by Endpoints News on July 2, 2026 1:43 PM

Read Original